Latest Healthcare News

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

NZX has appointed seasoned investment executive Hishaam Mirza as its new Chief Executive, aiming to boost the exchange's scale, liquidity, and international relevance.

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

Cogstate Ltd (ASX:CGS) posted a 15.9% rise in profit before tax to US$16.1 million for FY26, driven by a 116% surge in clinical trial sales contracts to $89 million and a 15% revenue increase. The company doubled its final dividend to A$0.04 per share, supported by a strong $118.5 million contracted revenue backlog.

HealthCo Healthcare & Wellness REIT delivered strong FY26 results with 100% rent collection and solid portfolio metrics, while progressing alternative lease arrangements for its Healthscope hospital portfolio.

Alice Queen Limited has bolstered its Horn Island gold project with an updated resource of 569,000 ounces and a robust Project Definition Study showing a pre-tax NPV of A$706 million. A 2026 drilling program is underway to test a large-scale Exploration Target of up to 2.3 million ounces.

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Eureka Group Holdings has acquired Townsville Lakes Holiday Park, adding 110 sites and targeting an 18.2% IRR through conversion to long-term rentals amid tight regional housing markets.

Doctor Care Anywhere delivered a 27% rise in EBITDA and doubled free cash flow in H1 2026, driven by operational efficiencies and a strategic entry into the UK weight management market via acquisition.

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.

GWA Group posted modest revenue and earnings growth in FY26, driven by volume gains across Australia, New Zealand, and the UK, while raising dividends and advancing strategic priorities despite challenging market conditions.

Marlin Global delivered a robust 3.1% gross portfolio return in July 2026, significantly outpacing its benchmark which fell 3.6%, thanks to strategic semiconductor underweighting and strong gains in tech giants Microsoft, Dexcom, and Amazon.